Results 211 to 220 of about 22,252 (260)

Comparison of mortality between echinocandins and polyenes for an initial treatment of candidemia: A systematic review and meta-analysis.

Journal of Infection and Chemotherapy, 2021
BACKGROUND Current guidelines recommend echinocandins for the initial treatment of candidemia. However, polyenes are often chosen in clinical settings because of their fungicidal and anti-biofilm effects.
Hideo Kato, M. Hagihara, Y. Shibata, N. Asai, Y. Yamagishi, T. Iwamoto, H. Mikamo   +6 more
semanticscholar   +1 more source

Comparative Effectiveness of Echinocandins vs Triazoles or Amphotericin B Formulations as Initial Directed Therapy for Invasive Candidiasis in Children and Adolescents.

Journal of the Pediatric Infectious Diseases Society, 2021
BACKGROUND Invasive candidiasis is the most common invasive fungal disease in children and adolescents, but there are limited pediatric-specific antifungal effectiveness data.
B. Fisher, T. Zaoutis, R. Xiao, Rachel L. Wattier, E. Castagnola, Z. Pana, Allison Fullenkamp, Craig L K Boge, R. Ross, I. Yildirim, D. Palazzi, L. Danziger-Isakov, Surabhi B. Vora, A. Arrieta, Dwight E. Yin, M. Avilés-Robles, Tanvi S. Sharma, A. Tribble, Gabriela M. Maron, D. Berman, Michael D. Green, L. Sung, J. Romero, S. Hauger, E. Roilides, K. Belani, D. Nolt, P. Soler-Palacín, Eduardo López-Medina, W. Muller, Natasha B Halasa, D. Dulek, I. Hussain, Alice Pong, J. Hoffman, S. Rajan, B. E. Gonzalez, B. Hanisch, Catherine Aftandilian, F. Carlesse, M. Abzug, A. Huppler, C. Salvatore, M. Ardura, A. Chakrabarti, M. Santolaya, A. Localio, W. Steinbach   +47 more
semanticscholar   +1 more source

Echinocandins in Children

Pediatric Infectious Disease Journal, 2011
The echinocandins (ECs), caspofungin (CA), micafungin (MI), anidulafungin (AD), and aminocandin (AM) are the newest class of parenterally administered antifungal agents. This review will discuss their general properties, current indications, and available pediatric data.
Jill A, Hoffman, Thomas J, Walsh
openaire   +4 more sources

Echinocandins: production and applications

Applied Microbiology and Biotechnology, 2013
The first echinocandin-type antimycotic (echinocandin B) was discovered in the 1970s. It was followed by the isolation of more than 20 natural echinocandins. These cyclic lipo-hexapeptides are biosynthesized on non-ribosomal peptide synthase complexes by different ascomycota fungi.
Tamás Emri
exaly   +3 more sources

Echinocandin antifungal drugs

Lancet, The, 2003
The echinocandins are large lipopeptide molecules that are inhibitors of beta-(1,3)-glucan synthesis, an action that damages fungal cell walls. In vitro and in vivo, the echinocandins are rapidly fungicidal against most Candida spp and fungistatic against Aspergillus spp.
exaly   +4 more sources

Echinocandins versus non-echinocandins for the treatment of invasive candidiasis: A meta-analysis of randomized controlled trials.

Journal of Infection and Chemotherapy, 2020
INTRODUCTION Echinocandins are frequent use antifungals in the treatment of invasive candidiasis, and it is important to update information on their efficacy and safety for optimal antifungal drug treatment.
Sho Tashiro, Sumika Osa, Yuki Igarashi, Yuki Watabe, Xiaoxi Liu, Y. Enoki, K. Taguchi, T. Mayumi, Y. Miyazaki, Y. Takesue, Kazuaki Matsumoto   +10 more
semanticscholar   +1 more source

Echinocandins in Ocular Therapeutics

Journal of Ocular Pharmacology and Therapeutics, 2017
Fungal infections of the eye, especially fungal keratitis and endophthalmitis, are major causes of concern and if left untreated could lead to vision loss. Currently, natamycin (polyene antifungal) is the only commercially available topical agent used for the treatment of ocular fungal infections.
Akash, Patil, Soumyajit, Majumdar
openaire   +2 more sources

Echinocandins for Candidemia

New England Journal of Medicine, 2006
Carolina Garcia-Vidal, Jordi Carratala
exaly   +2 more sources

Micafungin - The newest echinocandin

Drugs of Today, 2009
Micafungin is one of three currently FDA-approved echinocandins. It has potent in vitro activity against Candida species including non-albicans Candida and azole-resistant Candida species and has also demonstrated clinical efficacy against deep-seated Candida infections. Additional in vitro data and preliminary clinical efficacy studies suggest that it
Zelalem, Temesgen, Jason, Barreto, Sandro, Vento   +2 more
openaire   +2 more sources

Update on Echinocandin Antifungals

Seminars in Respiratory and Critical Care Medicine, 2008
Echinocandins are semisynthetic lipopeptides that competitively inhibit an essential cell wall component of Candida and aspergillus. They are generally inactive against other fungi. Resistance to these agents is infrequent to date. Echinocandins exhibit low oral bioavailability and are available only as parenteral formulations that are dosed once daily.
Carol A, Kauffman, Peggy L, Carver
openaire   +2 more sources